The short answer
Green tea extract has its own liver-injury concern, especially for concentrated high-dose products. Review it with your cancer team; the added risk specifically with adagrasib has not been measured.
What this answer covers
Oral Camellia sinensis leaf extracts during oral adagrasib treatment. Concentrated extracts and their EGCG content are distinct from brewed tea, caffeine content and total leaf weight.
- Supplement or preparation
- Camellia Sinensis Leaf Extract
- Medication ingredient
- adagrasib
The extract has its own liver signal
In a year-long randomized study, women taking green tea extract supplying 843 mg EGCG daily had more ALT liver-enzyme elevations than women taking placebo. Most adverse events were mild or transient, and overall serious adverse-event frequencies were not significantly different. The study did not test adagrasib.
Adagrasib already needs liver monitoring
Krazati can cause liver injury. Its label calls for liver tests before treatment, monthly for the first three months and as clinically indicated, with closer checks if enzymes rise. Adding a product with a separate liver signal makes review important, but does not establish a measured increase in combination risk.
Check EGCG and the full formulation
Bring the extract label and daily amount to the oncology pharmacist. The study’s EGCG dose is not the same as the total milligrams of leaf extract, and its results do not identify a safe lower dose during cancer treatment. A brewed drink or another preparation cannot simply be assigned the trial’s exposure.
Do not use food or spacing as a safety guarantee
Krazati may be taken with or without food, but that instruction does not show that food prevents supplement-related liver injury. No hours-apart schedule has been established for this concern. Report yellowing of the skin or eyes, dark urine or persistent upper-abdominal discomfort promptly to your cancer team.
Evidence and practical considerations
Side effects & toxicity
An increased liver-injury rate specifically from green tea extract combined with adagrasib has not been established.
- Exact scope
- Oral Camellia sinensis leaf extracts during oral adagrasib treatment. Concentrated extracts and their EGCG content are distinct from brewed tea, caffeine content and total leaf weight. with Exact adagrasib RxCUI 2625882 IN, confirmed by current RxNorm properties. Oral Krazati tablets; the August 2026 U.S. label covers single-agent treatment of specified previously treated KRAS G12C-mutated NSCLC. Older cetuximab combination cohorts and regional label instructions are not interchangeable.
- Medication form and route
- Oral
What remains uncertain
- The extract trial did not include adagrasib or establish the risk of every dose or preparation.
Factors that may matter: Exact preparation and dose; Treatment phase and duration; Liver function; Electrolyte results and GI symptoms; Other medicines.
Read the supporting source summaries
Source 1: Current U.S. prescribing information
bms.com · Source check Sep 10, 2026
Population: Adults with specified previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Warns about GI toxicity, QT prolongation and hepatotoxicity. Monitor/correct electrolytes, particularly potassium and magnesium, and monitor liver tests. Strong CYP3A inducers lower exposure. Avoid strong CYP3A inhibitors until steady state, approximately eight days. High-fat meal did not meaningfully change exposure; tablets may be taken with or without food.
How this applies: Exact current U.S. guidance; newer than the retained March 2026 DailyMed version. Exact adagrasib RxCUI 2625882 IN, confirmed by current RxNorm properties. Oral Krazati tablets; the August 2026 U.S. label covers single-agent treatment of specified previously treated KRAS G12C-mutated NSCLC. Older cetuximab combination cohorts and regional label instructions are not interchangeable.
Not direct evidence of each botanical combination. Strong-inhibitor effects after a single dose differ from steady-state model predictions. Effects of adagrasib on other CYP substrates are a separate direction. No universal supplement prescription.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 1075 postmenopausal women randomized in the Minnesota Green Tea Trial.
ALT elevations occurred in 6.7% of extract users versus 0.7% with placebo; overall and serious adverse-event frequencies were not significantly different. Most adverse events were mild and transient.
How this applies: Original high-dose extract safety signal supports a separate liver precaution, not measured additive toxicity.
Abstract-only: fullTextXML failed and the captured PMC HTML was a browser challenge, not source access. No adagrasib, no equivalence to brewed tea, all extract doses or cancer populations. ALT elevations are not all clinical liver failure.
Source 3: Authoritative medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Medication terminology.
Identifies adagrasib as IN.
How this applies: Exact identity confirmation.
Not clinical interaction evidence.
Research assessment: · Open full citations ↗
Side effects & toxicity
High-dose green tea extract has a liver-enzyme safety signal that warrants oncology review when adagrasib already requires liver monitoring.
- Exact scope
- Oral Camellia sinensis leaf extracts during oral adagrasib treatment. Concentrated extracts and their EGCG content are distinct from brewed tea, caffeine content and total leaf weight. with Exact adagrasib RxCUI 2625882 IN, confirmed by current RxNorm properties. Oral Krazati tablets; the August 2026 U.S. label covers single-agent treatment of specified previously treated KRAS G12C-mutated NSCLC. Older cetuximab combination cohorts and regional label instructions are not interchangeable.
- Medication form and route
- Oral
What remains uncertain
- Precaution based on separate toxicity evidence. Trial ALT elevations are not all clinical liver failure; no safe adagrasib-specific EGCG threshold or protective spacing interval established.
Factors that may matter: Exact preparation and dose; Treatment phase and duration; Liver function; Electrolyte results and GI symptoms; Other medicines.
Read the supporting source summaries
Source 1: Current U.S. prescribing information
bms.com · Source check Sep 10, 2026
Population: Adults with specified previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Warns about GI toxicity, QT prolongation and hepatotoxicity. Monitor/correct electrolytes, particularly potassium and magnesium, and monitor liver tests. Strong CYP3A inducers lower exposure. Avoid strong CYP3A inhibitors until steady state, approximately eight days. High-fat meal did not meaningfully change exposure; tablets may be taken with or without food.
How this applies: Exact current U.S. guidance; newer than the retained March 2026 DailyMed version. Exact adagrasib RxCUI 2625882 IN, confirmed by current RxNorm properties. Oral Krazati tablets; the August 2026 U.S. label covers single-agent treatment of specified previously treated KRAS G12C-mutated NSCLC. Older cetuximab combination cohorts and regional label instructions are not interchangeable.
Not direct evidence of each botanical combination. Strong-inhibitor effects after a single dose differ from steady-state model predictions. Effects of adagrasib on other CYP substrates are a separate direction. No universal supplement prescription.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 1075 postmenopausal women randomized in the Minnesota Green Tea Trial.
ALT elevations occurred in 6.7% of extract users versus 0.7% with placebo; overall and serious adverse-event frequencies were not significantly different. Most adverse events were mild and transient.
How this applies: Original high-dose extract safety signal supports a separate liver precaution, not measured additive toxicity.
Abstract-only: fullTextXML failed and the captured PMC HTML was a browser challenge, not source access. No adagrasib, no equivalence to brewed tea, all extract doses or cancer populations. ALT elevations are not all clinical liver failure.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: ba342a15a8ace9b0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.